Skip to main content

Table 1 Base-case annual probabilities associated with LAM-resistant CHB

From: Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China

Initial state

Entered state

HBeAg (+)

 

HBeAg (−)

 

Source

  

Estimate (%)

Range (%)

Estimate (%)

Range (%)

 

Lamivudine-resistant CHB

Compensated cirrhosis

2.7

1.6-3.8

6.2

2.8-9.7

[27]

 

Hepatocellular carcinoma

0.4

0.3-0.6

0.4

0.3-0.6

[27]

Virological response

Compensated cirrhosis

0.5

0.3-0.8

1.2

0.7-2

[25]

 

Hepatocellular carcinoma

0.2

0.1-0.4

0.2

0.1-0.4

[25]

Multi-resistant CHB

Compensated cirrhosis

2.7

1.6-3.8

6.2

2.8-9.7

[27]

 

Hepatocellular carcinoma

0.4

0.3-0.6

0.4

0.3-0.6

[27]

Compensated cirrhosis

Decompensated cirrhosis

7.3

3.5-10

7.3

3.5-10

[28]

 

Hepatocellular carcinoma

3.4

1-10

3.4

1-10

[28]

 

Death

4.9

2-14

4.9

2-14

[28]

Decompensated cirrhosis

Hepatocellular carcinoma

3.4

1-10

3.4

1-10

[28]

 

Liver transplantation

5

1-10

5

1-10

[5]

 

Death

14.4

10-20

14.4

10-20

[5]

Hepatocellular carcinoma

Liver transplantation

5

1-10

5

1-10

[5]

 

Death

23.3

20-30

23.3

20-30

[5]

Liver transplantation

Death

7

2-12

7

2-12

[5]

  1. CHB, chronic hepatitis B.